BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19552194)

  • 1. [Immunologic thrombocytopenic purpura: a revolution of biological therapy?].
    Bierling P; Godeau B
    Rev Prat; 2009 May; 59(5):606-7. PubMed ID: 19552194
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus.
    Lee JW; Kim HA; Sung JM; Suh CH
    Lupus; 2010 Feb; 19(2):227-8. PubMed ID: 19884220
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immune thrombocytopenic purpura: pathophysiology and treatment].
    Godeau B
    Transfus Clin Biol; 2009 May; 16(2):101-5. PubMed ID: 19409827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New therapies for immune thrombocytopenic purpura.
    Andemariam B; Bussel J
    Curr Opin Hematol; 2007 Sep; 14(5):427-31. PubMed ID: 17934347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab for chronic immune thrombocytopenic purpura.
    Bay A; Oner AF
    J Pediatr; 2006 Mar; 148(3):423-4; author reply 424. PubMed ID: 16615987
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura.
    Moschovi M; Trimis G; Pergantou H; Platokouki H; Vrachnou E; Tzortzatou-Stathopoulou F
    J Paediatr Child Health; 2005 Jul; 41(7):384-6. PubMed ID: 16014149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus.
    ten Cate R; Smiers FJ; Bredius RG; Lankester AC; van Suijlekom-Smit LW; Huizinga TW; Egeler RM
    Rheumatology (Oxford); 2004 Feb; 43(2):244. PubMed ID: 14739467
    [No Abstract]   [Full Text] [Related]  

  • 8. Splenectomy for treatment of immune thrombocytopenic purpura.
    Malcovati L; Della Porta MG
    Haematologica; 2005 Jan; 90(1):4. PubMed ID: 15644305
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
    Bengtson KL; Skinner MA; Ware RE
    J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab use in pediatric autoimmune diseases: four case reports.
    Polido-Pereira J; Ferreira D; Rodrigues AM; Nascimento C; Costa P; Almeida M; da Silva JE; Simão C; Stone R; Ramos F; Neto A; da Costa JC; Melo-Gomes J; Gomes-Pedro J; Viana-Queiroz M; Canhão H; Fonseca JE
    Ann N Y Acad Sci; 2009 Sep; 1173():712-20. PubMed ID: 19758220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for chronic immune thrombocytopenic purpura. Introduction.
    Pruemer J
    Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S3. PubMed ID: 19139488
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura.
    Benedetti L; Franciotta D; Beronio A; Cadenotti L; Gobbi M; Mancardi GL; Schenone A; Tartaglione A
    Muscle Nerve; 2008 Aug; 38(2):1076-7. PubMed ID: 18642360
    [No Abstract]   [Full Text] [Related]  

  • 13. Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab.
    El-Shanawany TM; Williams PE; Jolles S
    J Clin Pathol; 2007 Jun; 60(6):715-6. PubMed ID: 17483248
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab.
    Stosic M; De Jesus P; McCarthy J; Hutton G; Rivera V
    Neurology; 2011 Aug; 77(5):505-7. PubMed ID: 21775738
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of autoantibody-producing plasma cells in immune thrombocytopenic purpura refractory to rituximab.
    Kuwana M; Iki S; Urabe A
    Am J Hematol; 2007 Sep; 82(9):846-8. PubMed ID: 17506067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab: a new therapeutic tool for primary immune thrombocytopenic purpura?
    Introna M; Golay J; Barbui T
    Haematologica; 2003 May; 88(5):482-4. PubMed ID: 12745265
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura.
    Fianchi L; Rossi E; Murri R; De Stefano V; Pagano L; Leone G
    Ann Hematol; 2007 Mar; 86(3):225-6. PubMed ID: 17031685
    [No Abstract]   [Full Text] [Related]  

  • 18. [Immune thrombocytopenias: pathophysiology and treatment].
    Godeau B
    Bull Acad Natl Med; 2013 Feb; 197(2):407-17. PubMed ID: 24919370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune thrombocytopenia].
    Matzdorff A
    Dtsch Med Wochenschr; 2011 Jun; 136(22):1172-4. PubMed ID: 21611922
    [No Abstract]   [Full Text] [Related]  

  • 20. [Rituximab monoclonal antibody in the treatment of retractable idiopathic thrombocytopenic purpura--a case report].
    Zhou N; Hua BL; Wang SJ; Zhu TN; Zhao YQ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(6):432. PubMed ID: 15854541
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.